Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + Ramucirumab vs Paclitaxel + Placebo in Second-line Gastric/GEJ Adenocarcinoma (China)
CTR20160574Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Jan 2017; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20160574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160574.